ArticleThe Journal of biological chemistry2012
Chemically programmed bispecific antibodies that recruit and activate T cells.
Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Site-Specific Antibody Conjugation with Payloads beyond Cytotoxins.Molecules (Basel, Switzerland) · 2023Review
- Chemically Programmable and Switchable CAR-T Therapy.Angewandte Chemie (International ed. in English) · 2020Article
- Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1.Frontiers in immunology · 2019Article
- T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.Pharmacology & therapeutics · 2018Review
- Site-Specific Antibody Conjugation for ADC and Beyond.Biomedicines · 2017Review
- Stable and Potent Selenomab-Drug Conjugates.Cell chemical biology · 2017Article
- Chemically Programmed Bispecific Antibodies in Diabody Format.The Journal of biological chemistry · 2016Article
- Chemically synthesized molecules with the targeting and effector functions of antibodies.Journal of the American Chemical Society · 2014Article
- Improving the serum stability of site-specific antibody conjugates with sulfone linkers.Bioconjugate chemistry · 2014Article
- Chemically programmed antibodies.Trends in biotechnology · 2014Review
- Antibody conjugation via one and two C-terminal selenocysteines.Methods (San Diego, Calif.) · 2014Article
- Recruiting cytotoxic T cells to folate-receptor-positive cancer cells.Angewandte Chemie (International ed. in English) · 2013Article
- Bispecific small molecule-antibody conjugate targeting prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Bispecific antibodies (biAbs) that mediate cytotoxicity by recruiting and activating endogenous immune cells are an emerging class of next-generation antibody therapeutics. Of particular interest are biAbs of relatively small size (∼50 kDa) that can redirect cytotoxic T cells through simultaneous binding of tumor cells. Here we describe a conceptually unique class of biAbs in which the tumor cell specificity of a humanized antibody fragment that recognizes CD3 on T cells is chemically programmed through a C-terminal selenocysteine (Sec) residue. We demonstrate that through chemically programmed specificity for integrin α(4)β(1) or folate receptor 1 (FOLR1), and common specificity for CD3, these hybrid molecules exert potent and specific in vitro and ex vivo cytotoxicity toward tumor cell lines and primary tumor cells in the presence of primary T cells. Importantly, the generic nature of chemical programming allows one to apply our approach to virtually any specificity, promising a broad utility of chemically programmed biAbs in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.